Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib plus tislelizumab in advanced HCC
NCT04183088Phase 2Unknown
- Sponsor
- National Taiwan University Hospital
- Start
- Dec 2020
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tislelizumab in hepatocellular carcinoma (HCC), sponsored by National Taiwan University Hospital. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04183088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04183088.